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| INTRODUC TI ON
The number of new cases of colorectal cancer (CRC) is increasing rapidly worldwide, with high mortality and morbidity rates.
1,2 CRC presents a high rate of anticancer therapy failure, with local tumor recurrence or distant metastasis being reported in over 90% of malignant CRC cases. [3] [4] [5] [6] Furthermore, the malignant characterization of CRC shows abnormal proliferation, rapid diffuse infiltration and high resistance rate of therapeutic treatment. [6] [7] [8] [9] [10] Despite studies on CRC development and molecular characterization of CRC malignancy, therapeutic results are not fully satisfactory. 11, 12 Thus, elucidation of CRC malignancy-related target molecules and mechanism are required for developing more effective CRC therapies.
Hyaluronic acid (HA), or hyaluronan, is an essential component of the extracellular matrix (ECM), which regulates tissue stiffness, maintains stroma homeostasis and acts as a signaling component in many types of cells. 13, 14 This unbranched heteropolysaccharide is synthesized by HA synthase (HAS), which localizes to the cellular plasma membrane. Three types of HAS have been recognized (HAS1, HAS2 and HAS3) and HA of different sizes are secreted directly into the extracellular space. 15 Recently, the overexpression of HAS has been reported in bladder, lung, ovarian and breast cancers, where it has been related with malignant tumor phenotypes. [16] [17] [18] [19] HAS2,
in particular, appears to promote tumor proliferation, migration and invasion in many types of tumor. 18, 20 Furthermore, HAS2 can modulate the radiosensitivity of CRC through accumulation of DNA damage. 21 Given the established effects of HAS2 in many cancers, it may also contribute to the regulation of CRC malignancy. However, the role of HAS2 expression in CRC malignancy has not been reported. In this study, we investigated the regulatory role of HAS2 in CRC malignancy, especially its effect on the major regulatory steps of metastasis, such as therapeutic sensitivity and epithelial-mesenchymal transition (EMT). We found that HAS2 regulates the expression of transforming growth factor beta (TGF-β), an important tumor malignancy regulatory component, and that the HAS2-mediated regulation of CRC malignancy occurred independently of the HA ligand-mediated pathway. Taken together, our findings suggest the importance of HAS2 in CRC malignancy regulation and its potential as an effective therapeutic target for CRC.
| MATERIAL S AND ME THODS

| Reagents and antibodies
Antibodies against Slug (SC-10436), Twist (SC-15393) and β-actin anti-zeb1 (HPA027524) were from Abcam (MA, USA), Biovision (CA, USA) and Sigma (MO, USA), respectively. Hyaluronan (GLR001, low molecular weight; GLR004, middle molecular weight; GLR002, high molecular weight) was purchased from R&D Systems (MN, USA).
4-Methylumbelliferone (M1381) and SB431542 (S4317) was purchased from Sigma (MO, USA).
| Cell culture
HT29, WiDr, DLD1, HCT116, SW480, RKO CRC cells were obtained from the American Type Culture Collection. Cell lines were cultured in RPMI-1640 media containing 30 μg/mL gentamicin supplemented with 10% FBS. All cell lines were negative for mycoplasma contamination and were not passaged > 3 months upon thawing. Cells were cultured in a humidified 5% CO 2 atmosphere at 37°C.
| Western blot analysis
Cell lysates were prepared by incubating with lysis buffer (40 mmol/L Tris-HCl pH 8.0, 120 mmol/L NaCl, 0.1% Nonidet-P40) supplemented with protease inhibitors. Proteins in whole-cell lysates were separated by SDS-PAGE and transferred to a nitrocellulose membrane.
The membrane was blocked with 0.5% BSA in TBS and incubated with primary antibodies overnight at 4°C. Blots were developed with a peroxidase-conjugated secondary antibody, and proteins were visualized using enhanced chemiluminescence (ECL) procedures.
| Transfection
HCT116, DLD1 and SW480 were plated in 60 or 100 mm dishes in RPMI-1640 complete media. The following day, the complete medium was replaced, and cells were transfected with HAS2 siRNA or pcDNA3.1-HAS2 plasmid vector and negative scrambled control by using TransIT-X2 (Mirus, WI, USA).
| Tissue array
HAS2 expression was quantified using tissue array containing 32
human CRC tissues with corresponding normal tissues (ISU ABXIS, Seoul, Korea). For immunohistochemical analysis, tissues were treated with 0.3% hydrogen peroxide in methyl alcohol for 20 minutes to block endogenous peroxidase activity. After 3 washes with PBS, sections were blocked with 10% normal goat serum (Vector Laboratories, CA, USA) and incubated with anti-HAS2 antibody.
After 3 subsequent washes with PBS, sections were incubated with HRP-conjugated secondary antibody (Dako, CA, USA). A diaminobenzidine substrate was used for detection. Quantitative assessment of immunoreactivity was performed with i-solution software.
| Irradiation
Cells in culture medium were plated in 60 and 100-mm dishes and incubated at 37°C in a humidified 5% CO 2 atmosphere. Cells were exposed to 10 Gy radiation using a Gammacell-3000 Elan irradiator (137Cs γ-ray source; MDS, ON, Canada). 
| Invasion and migration assays
| Animal experiment
| Immunocytochemistry
Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS. Following fixation, cells were incubated at 4°C overnight with anti-human HAS2, anti-E-cadherin and antiVimentin primary antibodies in PBS with 1% BSA and 0.1% Triton X-100. Stained proteins were visualized using Alexa Fluor 488-conjugated secondary antibodies (Thermo Fisher Scientific, MA, USA).
Nuclei were counterstained with DAPI (Sigma, MO, USA). Stained cells were observed with an Olympus IX71 fluorescence microscope (Olympus).
| ELISA
Concentrations of Hyaluronan in CRC cell culture medium were quantified by a sandwich enzyme immunoassay using the Quantikine ELISA kit (R&D Systems) following the manufacturer's instructions.
Absorbance at 450 nm was measured using a microplate reader (BioTek microplate reader).
| Statistical analysis
All experiments were repeated 3 times or more. Comparisons between values were performed using unpaired two-tailed Student's t-test, or ANOVA for multivariate analysis. The variance was similar between groups that were being statistically compared. All statistical analyses were performed using GraphPad Prism 7.0 and the P values < 0.05 were considered significant.
| RE SULTS
| HAS2 expression correlates with the malignant phenotype of colorectal cancer tissues and cell lines
To investigate the role of HAS2 in CRC, we first compared the expression levels of HAS2 between neoplastic and non-neo- 
| Knockdown of HAS2 sensitizes colorectal cancer cells to anticancer treatment
Because high levels of HAS2 were related to apoptosis of CRC in response to anticancer treatment, we postulated that HAS2 might have a role in CRC malignancy. Hence, we depleted endogenous HAS2 molecule by siRNA transfection system in the HCT116 and DLD1 cell lines, which express high levels of HAS2
( Figure 2A ). Importantly, knockdown of HAS2 reduced the growing ability ( Figure 2B ) and colony formation efficiency of the malignant CRC cell lines ( Figure 2C ). Colony forming ability could be suggestive of cell responses such as proliferation, differentiation and cell death. 22 Therefore, we tested whether HAS2 depletion could sensitize CRC cells to radiation and oxaliplatin. By FACS analysis using Annexin V and propidium iodide (PI) double staining, measurement of apoptosis of CRC cells after transfection with HAS2 siRNA followed by treatment with radiation or oxaliplatin indicated an increase in apoptotic cell death ( Figure 2D ). In agreement with these results, the cleaved forms of caspase-3 and PARP, the hallmarks of apoptosis, 23 were increased in HAS2-depleted CRC cells compared with that in the control cells ( Figure 2E ). Collectively, these data suggest that HAS2 depletion sensitizes CRC cells to anticancer treatment.
| Knockdown of HAS2 suppresses metastatic ability of colorectal cancer cells through epithelialmesenchymal transition
To further investigate the role of HAS2 in CRC malignancy regulation, we next examined the effect of HAS2 on the metastatic ability of CRC. To this end, we first investigated migration and invasion of HCT116 and DLD1 CRC cells after transfection with HAS2 siRNA.
By Boyden chamber assay, we observed that siRNA-mediated HAS2 depletion effectively suppresses migration and invasion of these CRC cells ( Figure 3A ). Many studies suggested that the migration and invasion properties of cancer cells are associated with the EMT program. 24 To examine the role of HAS2 in EMT, we analyzed EMT markers and transcriptional activators after treatment with HAS2 siRNA. Our western blot analysis indicated that HAS2 is a critical EMT regulator in CRC cells, as evidenced by expression levels of EMT markers (E-cadherin, N-cadherin and Vimentin) and its master transcription factors (Zeb1 and Snail) ( Figure 3B) . A similar observation was obtained by immunocytochemical analysis in which E-cadherin was increased, while Vimentin was decreased by HAS2 depletion ( Figure 3C ). Based on these in vitro data, we attempted to validate the effect of HAS2 on in vivo metastasis of CRC. HCT116 cells were transfected with HAS2 shRNA or scrambled control shRNA prior to injection into the spleen of athymic nude mice. Three shRNA. Data are presented as mean ± SD from one of three independent experiments with similar results. *P < 0.05 vs control; **P < 0.01 vs control; ***P < 0.001 vs control weeks later, these mice were sacrificed and the metastasis was analyzed. Notably, control shRNA-transfected HCT116 cells were easily metastasized into the liver; however, HAS2-depleted HCT116 cells
were not metastasized ( Figure 3D,E) . Collectively, these data suggest that HAS2 depletion suppressed the metastatic ability of CRC cells through EMT regulation.
| Overexpression of HAS2 confers malignancy on colorectal cancer cells
In addition to HAS2 knockdown, we overexpressed HAS2 in SW480 colorectal cancer cell lines. The overexpression of HAS2 was confirmed by western blotting ( Figure 4A is a critical factor of CRC malignancy regulation.
| Hyaluronic acid ligand has no effect on colorectal cancer malignancy
To investigate the role of HAS2 in CRC malignancy regulation, we initially analyzed HA, the enzymatic product of HAS2. HA is a wellknown glycosaminoglycan ECM component in most mammalian tissues. This natural component has gained attention as an interesting target molecule for cancer due to its fundamental ability to act as a ligand. First, we examined the HA secretion level in CRC cell lines to check malignancy and hyaluronan correlation. However, ELISA analysis showed that secreted HA has no correlation with the cell malignancy status ( Figure 5A ). In addition, to identify the direct 
| Overexpression of HAS2 mediates colorectal cancer malignancy via SMAD activation
We observed that HAS2 expression correlated with TGF-β/SMAD complexation in malignant CRC cells. In parallel with these findings, HAS2 overexpression increased TGF-β expression and the phosphorylation of SMAD proteins in SW480 CRC cell lines, which showed low malignancy ( Figure 7A ). Next, to assess the direct effect of HAS2 on TGF-β/Smad2/3 signaling, we treated SB431542
to the SW480 overexpressing cell lines with HAS2. Although 
| D ISCUSS I ON
Despite advancements in anticancer therapeutic strategies, including surgery, chemotherapy using agents such as oxaliplatin, irinotecan, fluorouracil and radiotherapy, 8 It is a well-known phenomenon that causes the metastatic spread of cancer cells and cancer recurrence. 32 In addition, acquisition of EMT features has been associated with therapeutic resistance. 33 Hyaluronic acid is a well-known glycosaminoglycan ECM component in most mammalian tissues. This natural component has gained attention as an interesting target molecule for cancer due to its fundamental ability to act as a ligand of CD44 and RHAMM. 34 The interactions of CD44 and RHAMM with HA are well known to be crucial role for tumor cell malignancy via various signaling pathways such as SRC, PI3k and MAPK, in many types of tumor. 35, 36 We examined whether the ligand of HA has an effect on CRC by treating cells with recombinant HA. Interestingly, the results revealed that treatment with HA of different sizes had no specific effect on CRC malignancy. This finding is consistent with some recent reports that the HA ligand-related pathway has no effect on regulating cellular behavior. 37, 38 Our results demonstrated that secreted HA ligand has less influence on CRC; however, overexpressed HAS2 regulates CRC malignancy crucially. This led us to postulate that HAS2 has a specific role in CRC malignancy regulation independent of HA synthase. TGF-β is one of the major regulators of cell and tissue behavior such as homeostasis, wound healing, fibrosis, angiogenesis and differentiation. 39 The TGF-β ligand and receptor complex phosphorylates downstream regulator protein SMAD. The phosphorylated SMAD forms a complex with co-SMAD and enters the nucleus to act as a gene transcriptional activator. 40 Previous studies have shown that once carcinogenesis is initiated, the TGF-β signaling pathway promotes cancer malignancy. Furthermore, TGF-β has often been associated with resistance to cancer treatment, increased risk of invasion and metastasis, poor prognosis, and high levels of microsatellite instability. [41] [42] [43] Hence, targeting the TGF-β pathway for cancer therapy could be regarded as a logical strategy. In the current study, we found that the TGF-β/SMAD2/ Snail signaling axis is closely associated with the malignancy of CRC cell lines and HAS2 regulates TGF-β expression. Both SMAD2
and SMAD3 have malignancy regulation ability. However, SMAD2
activation showed a more dramatic response in the CRC samples and SMAD2 has been reported to be correlated with CRC malignancy. 44 Several studies suggest that intracellular hyaluronan and HAS are involved in physiological events or conditions such as inflammation or cancer. 45, 46 In agreement with these studies, we anticipate intracellular HAS2 to be related with CRC malignancy regulation. Furthermore, HAS2 has a multi-pass membrane bound enzyme structure and may interact with other cytoplasmic proteins such as protein kinase C that are involved in TGF-β signaling. 47 In addition, recent studies have reported that TGF-β upregulates HAS2 expression. 38 
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